AU2176099A - Novel dosage form - Google Patents

Novel dosage form Download PDF

Info

Publication number: AU2176099A
Authority: AU; Australia
Prior art keywords: dose unit; pharmaceutical dose; drug; coating; food
Prior art date: 1998-01-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU21760/99A

Other languages

English (en)

Inventor

Lisbeth Illum

Peter James Watts

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kyowa Kirin Services Ltd

Original Assignee

West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-22

Filing date

1999-01-20

Publication date

1999-08-09

1999-01-20 Application filed by West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd filed Critical West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd

1999-08-09 Publication of AU2176099A publication Critical patent/AU2176099A/en

Status Abandoned legal-status Critical Current

Links

239000002552 dosage form Substances 0.000 title description 4
239000003814 drug Substances 0.000 claims description 73
229940079593 drug Drugs 0.000 claims description 70
235000013305 food Nutrition 0.000 claims description 56
239000002775 capsule Substances 0.000 claims description 52
238000000576 coating method Methods 0.000 claims description 40
239000011248 coating agent Substances 0.000 claims description 37
210000002784 stomach Anatomy 0.000 claims description 31
239000000463 material Substances 0.000 claims description 29
238000010521 absorption reaction Methods 0.000 claims description 20
229920002472 Starch Polymers 0.000 claims description 18
235000019698 starch Nutrition 0.000 claims description 18
210000000813 small intestine Anatomy 0.000 claims description 16
239000008107 starch Substances 0.000 claims description 16
229920003149 Eudragit® E 100 Polymers 0.000 claims description 13
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical group COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 claims description 13
238000000034 method Methods 0.000 claims description 13
229920000642 polymer Polymers 0.000 claims description 10
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 8
229960000830 captopril Drugs 0.000 claims description 8
238000000926 separation method Methods 0.000 claims description 7
229940122388 Thrombin inhibitor Drugs 0.000 claims description 4
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
239000003868 thrombin inhibitor Substances 0.000 claims description 4
229940122361 Bisphosphonate Drugs 0.000 claims description 3
108010010803 Gelatin Proteins 0.000 claims description 3
108010007859 Lisinopril Proteins 0.000 claims description 3
239000004098 Tetracycline Substances 0.000 claims description 3
150000004663 bisphosphonates Chemical class 0.000 claims description 3
229920000159 gelatin Polymers 0.000 claims description 3
239000008273 gelatin Substances 0.000 claims description 3
235000019322 gelatine Nutrition 0.000 claims description 3
235000011852 gelatine desserts Nutrition 0.000 claims description 3
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 3
235000019364 tetracycline Nutrition 0.000 claims description 3
150000003522 tetracyclines Chemical class 0.000 claims description 3
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
LPUDGHQMOAHMMF-JBACZVJFSA-N (2s)-2-[[[(2s)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(C[C@@H](CNC(=O)[C@H](CCCCN)NS(=O)(=O)C)C(O)=O)CCCC1 LPUDGHQMOAHMMF-JBACZVJFSA-N 0.000 claims description 2
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 claims description 2
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 2
XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 claims description 2
RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 2
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 2
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 2
239000004100 Oxytetracycline Substances 0.000 claims description 2
229930189077 Rifamycin Natural products 0.000 claims description 2
229960003022 amoxicillin Drugs 0.000 claims description 2
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
229960000723 ampicillin Drugs 0.000 claims description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims description 2
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims description 2
229940106164 cephalexin Drugs 0.000 claims description 2
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
229960002286 clodronic acid Drugs 0.000 claims description 2
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
229960004125 ketoconazole Drugs 0.000 claims description 2
229960004502 levodopa Drugs 0.000 claims description 2
229940042016 methacycline Drugs 0.000 claims description 2
GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims description 2
229960000515 nafcillin Drugs 0.000 claims description 2
229960000625 oxytetracycline Drugs 0.000 claims description 2
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 2
235000019366 oxytetracycline Nutrition 0.000 claims description 2
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
229960001639 penicillamine Drugs 0.000 claims description 2
229960005222 phenazone Drugs 0.000 claims description 2
229960003292 rifamycin Drugs 0.000 claims description 2
HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims description 2
229950001780 sampatrilat Drugs 0.000 claims description 2
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 2
229960002180 tetracycline Drugs 0.000 claims description 2
229930101283 tetracycline Natural products 0.000 claims description 2
229960000278 theophylline Drugs 0.000 claims description 2
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 1
230000001771 impaired effect Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 10
238000004090 dissolution Methods 0.000 description 8
230000000694 effects Effects 0.000 description 7
235000012054 meals Nutrition 0.000 description 7
VQCBHWLJZDBHOS-UHFFFAOYSA-N erbium(iii) oxide Chemical compound O=[Er]O[Er]=O VQCBHWLJZDBHOS-UHFFFAOYSA-N 0.000 description 6
230000009246 food effect Effects 0.000 description 6
235000021471 food effect Nutrition 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
230000004584 weight gain Effects 0.000 description 6
235000019786 weight gain Nutrition 0.000 description 6
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
229920000881 Modified starch Polymers 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
210000000936 intestine Anatomy 0.000 description 5
235000019426 modified starch Nutrition 0.000 description 5
230000000717 retained effect Effects 0.000 description 5
229920003134 Eudragit® polymer Polymers 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
239000002253 acid Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000010410 layer Substances 0.000 description 3
230000003183 myoelectrical effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
210000001187 pylorus Anatomy 0.000 description 3
230000009467 reduction Effects 0.000 description 3
SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
239000003782 beta lactam antibiotic agent Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000003139 buffering effect Effects 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003550 marker Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
229940056501 technetium 99m Drugs 0.000 description 2
JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
229920001612 Hydroxyethyl starch Polymers 0.000 description 1
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
244000078856 Prunus padus Species 0.000 description 1
241000657513 Senna surattensis Species 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
230000010405 clearance mechanism Effects 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
229920001688 coating polymer Polymers 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
238000013481 data capture Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 1
238000011978 dissolution method Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009506 drug dissolution testing Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
235000015201 grapefruit juice Nutrition 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000001341 hydroxy propyl starch Substances 0.000 description 1
229940050526 hydroxyethylstarch Drugs 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
JEHASHUIFUSSAI-UHFFFAOYSA-N sulfanylidenetechnetium Chemical compound [Tc]=S JEHASHUIFUSSAI-UHFFFAOYSA-N 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229910021642 ultra pure water Inorganic materials 0.000 description 1
239000012498 ultrapure water Substances 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AU21760/99A 1998-01-22 1999-01-20 Novel dosage form Abandoned AU2176099A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9801363		1998-01-22
GBGB9801363.4A GB9801363D0 (en)	1998-01-22	1998-01-22	Novel dosage form
PCT/GB1999/000193 WO1999037290A1 (fr)	1998-01-22	1999-01-20	Nouvelle forme posologique

Publications (1)

Publication Number	Publication Date
AU2176099A true AU2176099A (en)	1999-08-09

Family

ID=10825713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU21760/99A Abandoned AU2176099A (en)	1998-01-22	1999-01-20	Novel dosage form

Country Status (9)

Country	Link
EP (1)	EP1059918A1 (fr)
JP (1)	JP2002501016A (fr)
AR (1)	AR014467A1 (fr)
AU (1)	AU2176099A (fr)
CA (1)	CA2318257A1 (fr)
GB (1)	GB9801363D0 (fr)
NO (1)	NO20003640L (fr)
WO (1)	WO1999037290A1 (fr)
ZA (1)	ZA99454B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109453166A (zh) *	2018-10-16	2019-03-12	丹诺医药(苏州）有限公司	一种利福霉素-喹嗪酮偶联分子的固体分散体及其应用

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9910773D0 (en) *	1999-05-11	1999-07-07	West Pharm Serv Drug Res Ltd	Novel single unit coated dosage forms that can be used to minimise the effect of food on the absorption of drugs from the gastrointestinal tract
GB0102342D0 (en) *	2001-01-30	2001-03-14	Smithkline Beecham Plc	Pharmaceutical formulation
WO2006020009A1 (fr) *	2004-07-23	2006-02-23	The Procter & Gamble Company	Dosage oral solide formant un bisphosphonate et contenant un agent chélateur
CA2789097C (fr)	2005-04-28	2017-02-21	Proteus Digital Health, Inc.	Systeme pharma-informatique
US8802183B2 (en)	2005-04-28	2014-08-12	Proteus Digital Health, Inc.	Communication system with enhanced partial power source and method of manufacturing same
US8836513B2 (en)	2006-04-28	2014-09-16	Proteus Digital Health, Inc.	Communication system incorporated in an ingestible product
US9198608B2 (en)	2005-04-28	2015-12-01	Proteus Digital Health, Inc.	Communication system incorporated in a container
US8912908B2 (en)	2005-04-28	2014-12-16	Proteus Digital Health, Inc.	Communication system with remote activation
CN101496042A (zh)	2006-05-02	2009-07-29	普罗秋斯生物医学公司	患者定制的治疗方案
EP2083680B1 (fr)	2006-10-25	2016-08-10	Proteus Digital Health, Inc.	Système d'identification ingérable à activation commandée
WO2008063626A2 (fr)	2006-11-20	2008-05-29	Proteus Biomedical, Inc.	Récepteurs de signaux de santé personnelle à traitement actif du signal
AU2008210291B2 (en)	2007-02-01	2013-10-03	Otsuka Pharmaceutical Co., Ltd.	Ingestible event marker systems
CN101636865B (zh)	2007-02-14	2012-09-05	普罗秋斯生物医学公司	具有高表面积电极的体内电源
US9270025B2 (en)	2007-03-09	2016-02-23	Proteus Digital Health, Inc.	In-body device having deployable antenna
EP2124725A1 (fr)	2007-03-09	2009-12-02	Proteus Biomedical, Inc.	Dispositif dans le corps ayant un émetteur multidirectionnel
US8115618B2 (en)	2007-05-24	2012-02-14	Proteus Biomedical, Inc.	RFID antenna for in-body device
US8961412B2 (en)	2007-09-25	2015-02-24	Proteus Digital Health, Inc.	In-body device with virtual dipole signal amplification
EP2215726B1 (fr)	2007-11-27	2018-01-10	Proteus Digital Health, Inc.	Systèmes de communication transcorporelle utilisant des canaux de communication
EP3235491B1 (fr)	2008-03-05	2020-11-04	Proteus Digital Health, Inc.	Marqueurs et systèmes d'événement de communication multimode ingérables
AU2009268827B2 (en)	2008-07-08	2013-10-24	Proteus Digital Health, Inc.	Ingestible event marker data framework
EP2313003B1 (fr)	2008-08-13	2016-08-03	Proteus Digital Health, Inc.	Circuits pouvant être ingérés
JP2012514799A (ja)	2009-01-06	2012-06-28	プロテウスバイオメディカルインコーポレイテッド	摂取に関連するバイオフィードバックおよび個別薬物療法の方法およびシステム
US8540664B2 (en)	2009-03-25	2013-09-24	Proteus Digital Health, Inc.	Probablistic pharmacokinetic and pharmacodynamic modeling
EP2424427B1 (fr)	2009-04-28	2021-06-16	Otsuka Pharmaceutical Co., Ltd.	Marqueurs d'évènement comestibles à haute fiabilité
US9149423B2 (en)	2009-05-12	2015-10-06	Proteus Digital Health, Inc.	Ingestible event markers comprising an ingestible component
TWI517050B (zh)	2009-11-04	2016-01-11	普羅托斯數位健康公司	供應鏈管理之系統
SG10201502720VA (en)	2010-04-07	2015-05-28	Proteus Digital Health Inc	Miniature ingestible device
TWI557672B (zh)	2010-05-19	2016-11-11	波提亞斯數位康健公司	用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
US9107806B2 (en)	2010-11-22	2015-08-18	Proteus Digital Health, Inc.	Ingestible device with pharmaceutical product
US9756874B2 (en)	2011-07-11	2017-09-12	Proteus Digital Health, Inc.	Masticable ingestible product and communication system therefor
WO2015112603A1 (fr)	2014-01-21	2015-07-30	Proteus Digital Health, Inc.	Produit ingérable pouvant être mâché et système de communication associé
UA118745C2 (uk)	2011-07-21	2019-03-11	Протеус Діджитал Хелс, Інк.	Пристрій, система та спосіб мобільного зв'язку
US9235683B2 (en)	2011-11-09	2016-01-12	Proteus Digital Health, Inc.	Apparatus, system, and method for managing adherence to a regimen
CN104487347B (zh)	2012-07-23	2017-09-01	普罗秋斯数字健康公司	用于制造包括电子器件的片剂的方法和系统
AU2013331417B2 (en)	2012-10-18	2016-06-02	Proteus Digital Health, Inc.	Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
WO2014120669A1 (fr)	2013-01-29	2014-08-07	Proteus Digital Health, Inc.	Films polymères hautement dilatables et compositions les contenant
JP5941240B2 (ja)	2013-03-15	2016-06-29	プロテウスデジタルヘルス，インコーポレイテッド	金属検出器装置、システム、および方法
JP6511439B2 (ja)	2013-06-04	2019-05-15	プロテウスデジタルヘルス，インコーポレイテッド	データ収集および転帰の査定のためのシステム、装置、および方法
US9796576B2 (en)	2013-08-30	2017-10-24	Proteus Digital Health, Inc.	Container with electronically controlled interlock
US10084880B2 (en)	2013-11-04	2018-09-25	Proteus Digital Health, Inc.	Social media networking based on physiologic information
US11051543B2 (en)	2015-07-21	2021-07-06	Otsuka Pharmaceutical Co. Ltd.	Alginate on adhesive bilayer laminate film
SG11201900511VA (en)	2016-07-22	2019-02-27	Proteus Digital Health Inc	Electromagnetic sensing and detection of ingestible event markers
WO2018081337A1 (fr)	2016-10-26	2018-05-03	Proteus Digital Health, Inc.	Procédés de préparation de capsules avec des marqueurs d'événement ingérables
US11458104B1 (en) *	2018-06-21	2022-10-04	Mission Pharmacal Company	Enteric coated tiopronin tablet
CN110613697A (zh) *	2019-10-30	2019-12-27	长春迪瑞制药有限公司	一种头孢氨苄胶囊及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4786508A (en) *	1986-05-30	1988-11-22	Warner-Lambert Company	Coated dosage forms
FR2618331B1 (fr) *	1987-07-23	1991-10-04	Synthelabo	Compositions pharmaceutiques utiles pour le traitement de l'uremie
AU618589B2 (en) *	1988-04-05	1992-01-02	Kyowa Hakko Kogyo Co. Ltd.	Oral compositions for ruminants

1998
- 1998-01-22 GB GBGB9801363.4A patent/GB9801363D0/en not_active Ceased
1999
- 1999-01-20 CA CA002318257A patent/CA2318257A1/fr not_active Abandoned
- 1999-01-20 EP EP99901758A patent/EP1059918A1/fr not_active Withdrawn
- 1999-01-20 AU AU21760/99A patent/AU2176099A/en not_active Abandoned
- 1999-01-20 WO PCT/GB1999/000193 patent/WO1999037290A1/fr not_active Ceased
- 1999-01-20 JP JP2000528272A patent/JP2002501016A/ja active Pending
- 1999-01-21 ZA ZA9900454A patent/ZA99454B/xx unknown
- 1999-01-22 AR ARP990100264A patent/AR014467A1/es unknown
2000
- 2000-07-14 NO NO20003640A patent/NO20003640L/no not_active Application Discontinuation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109453166A (zh) *	2018-10-16	2019-03-12	丹诺医药(苏州）有限公司	一种利福霉素-喹嗪酮偶联分子的固体分散体及其应用

Also Published As

Publication number	Publication date
AR014467A1 (es)	2001-02-28
JP2002501016A (ja)	2002-01-15
WO1999037290A1 (fr)	1999-07-29
NO20003640D0 (no)	2000-07-14
CA2318257A1 (fr)	1999-07-29
ZA99454B (en)	2000-10-23
EP1059918A1 (fr)	2000-12-20
GB9801363D0 (en)	1998-03-18
NO20003640L (no)	2000-09-12

Publication	Publication Date	Title
AU2176099A (en)	1999-08-09	Novel dosage form
FI118626B (fi)	2008-01-31	Kooloniin annettava lääkekoostumus
AU707587B2 (en)	1999-07-15	Composition for enhanced uptake of polar drugs from the colon
KR100220322B1 (ko)	1999-09-15	장질환 치료를 위한 서방성 경구 투약 제형
ES2226412T3 (es)	2005-03-16	Proparaciones farmaceuticas de liberacion sostenida que comprende fenitoina sodica.
JP3249970B2 (ja)	2002-01-28	ペプチドを経口投与するための安定化組成物
US7445795B2 (en)	2008-11-04	Delivery device, method of using and method of manufacturing
CZ294641B6 (cs)	2005-02-16	Perorální přípravek s opožděným pulzním uvolňováním a způsob jeho přípravy
JP2002537321A (ja)	2002-11-05	促進剤を含む固体経口剤形
EP1916995B1 (fr)	2015-10-28	Système de distribution pulsatile commandé par le ph, procédés de préparation et utilisation
Ilhan et al.	2017	Mini tablets: A short review-revision
JP2967492B2 (ja)	1999-10-25	腸内適所放出経口製剤
JP5013871B2 (ja)	2012-08-29	経口徐放性医薬組成物
Dobson et al.	2000	Does the site of intestinal delivery of oleic acid alter the ileal brake response?
Fürst et al.	2005	Enteric‐coated cholylsarcosine microgranules for the treatment of short bowel syndrome
Nykänen	2003	Development of multiple-unit oral formulations for colon-specific drug delivery using enteric polymers and organic acids as excipients
More et al.	2023	Duocapsule and alternative shell material to gelatin: Advancement in capsule formulation
GB2365336A (en)	2002-02-20	Multiple capsules
Reshma	2013	Formulation and Evaluation of Olmesartan Medoxomil Pulsatile Drug Delivery System
THEOPHYLLINE	2006	Master of Pharmacy in Pharmaceutics
GB2324962A (en)	1998-11-11	Chromone compositions for bio-availability to the small intestine
NZ565272A (en)	2010-05-28	pH-controlled pulsatile delivery system, methods for preparation and use thereof
WO1998051300A1 (fr)	1998-11-19	Traitement d'etats allergiques

Legal Events

Date	Code	Title	Description
2003-07-03	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted

AU2176099A - Novel dosage form - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=10825713

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (45)

Family Cites Families (3)

Cited By (1)

Also Published As

Similar Documents

Legal Events